💉Notice of Membership Changes in Drug Development Consortium
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Summary
The Department of Justice issued a notice regarding the Subcutaneous Drug Development & Delivery Consortium's membership changes, adding notable companies like Gilead Sciences and Regeneron Pharmaceuticals. The notice outlines the consortium's authority under the National Cooperative Research and Production Act, emphasizing its aim to limit antitrust liability while maintaining openness to new members.
Agencies
- Justice Department
- Antitrust Division
Business Impact
$$ - Med
The notice pertains to changes in membership for the Subcutaneous Drug Development & Delivery Consortium, which is significant for antitrust regulations affecting collaborative business ventures. This impacts businesses involved in drug development, offering an avenue for potential collaborations while also laying out compliance requirements under the National Cooperative Research and Production Act of 1993.